Private company

Trillium Therapeutics Inc.

Trillium Therapeutics Inc. is a Canadian pharmaceutical preparations company, incorporated in British Columbia.1 It is headquartered in Mississauga, Canada.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersMississauga, Canada1
  • Incorporated inBritish Columbia, Canada2
  • Business address2488 Dunwin Drive, Mississauga, A6 L5L 1J92
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-41523.6%Operating margin3
-40098.6%Net margin3
19.4%Revenue growth, 20203
-21.3%Return on equity3

Where the money goes

Where each dollar of revenue went, fiscal 2020

  • Research and development100¢$25.3M
  • Income tax0¢$102.0K

Out of $148.0K in revenue.3 The company lost money this year.

Financial statements

Revenue43$148.0K in 2020
0$50.0K$100.0K$150.0K2018: $0$020182019: $124.0K$124.0K20192020: $148.0K$148.0K2020+19%
Operating income43-$61.5M in 2020+69% since 2018
-$80.0M-$60.0M-$40.0M-$20.0M02018: -$36.4M-$36.4M20182019: -$32.3M-$32.3M2019−11%2020: -$61.5M-$61.5M2020+90%
Net income43-$59.3M in 2020+81% since 2018
-$60.0M-$40.0M-$20.0M02018: -$32.9M-$32.9M20182019: -$38.1M-$38.1M2019+16%2020: -$59.3M-$59.3M2020+56%
Fiscal year2017201820192020
Revenue$04$124.0K3$148.0K3
Research and development$26.7M3$25.3M3
Operating income-$36.4M4-$32.3M3-$61.5M3
Income tax$28.0K3$102.0K3
Net income-$32.9M4-$38.1M3-$59.3M3

Compare Trillium Therapeutics Inc. with another company

Corporate structure

Trillium Therapeutics Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Trillium Therapeutics Inc.

  • Growth Equity Opportunities V, LLC Filed SC 13D/A on Trillium Therapeutics Inc., latest Nov 19, 2021
  • RA CAPITAL MANAGEMENT, L.P. Filed SC 13G/A on Trillium Therapeutics Inc., latest Nov 15, 2021
  • Trillium Therapeutics Inc. Mississauga, Canada

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Trillium Therapeutics Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$3.9M3 Dec 31, 2020$3.9M3 Dec 31, 20190%
Accumulated depreciation$3.1M3 Dec 31, 2020$2.5M3 Dec 31, 2019+23.7%
Property and equipment, net$778.0K3 Dec 31, 2020$1.4M3 Dec 31, 2019−43.2%
Operating-lease assets (leased space)$732.0K3 Dec 31, 2020$949.0K3 Dec 31, 2019−22.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$247.6M3 Dec 31, 2020$14.6M3 Dec 31, 2019+1597.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$783.0K3 Dec 31, 2020$783.0K3 Dec 31, 20190%

Leadership

Who has led Trillium Therapeutics Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jan Skvarka2021

President

  1. Jan Skvarka2021

Chief financial officer

  1. James T. Parsons2021
2025
Board members and other officers (13)

Timeline

  1. Nov 17, 20218-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights21
  2. Nov 16, 20218-K Other events22
  3. Oct 29, 20218-K Other events23
  4. Oct 27, 20218-K Shareholder vote; Regulation FD disclosure24
  5. Oct 20, 20218-K Other events25
  6. Oct 15, 20218-K Other events26
  7. Oct 13, 20218-K Other events27
  8. Jan 4, 2021New chief executive Jan Skvarka becomes CEO7

Filings

35 filings to the SEC since October 2021: 1 quarterly reports, 7 major events, 14 insider forms, 2 large holders, 11 other. The latest 20:

  1. Nov 29, 202115-12B EDGAR
  2. Nov 19, 2021EFFECT EDGAR
  3. Nov 19, 2021EFFECT EDGAR
  4. Nov 19, 20214 FORM 4 SUBMISSION EDGAR
  5. Nov 19, 20214 OWNERSHIP DOCUMENT EDGAR
  6. Nov 19, 20214 OWNERSHIP DOCUMENT EDGAR
  7. Nov 19, 20214 OWNERSHIP DOCUMENT EDGAR
  8. Nov 19, 20214 OWNERSHIP DOCUMENT EDGAR
  9. Nov 19, 20214 OWNERSHIP DOCUMENT EDGAR
  10. Nov 19, 20214 OWNERSHIP DOCUMENT EDGAR
  11. Nov 19, 20214 OWNERSHIP DOCUMENT EDGAR
  12. Nov 19, 20214 OWNERSHIP DOCUMENT EDGAR
  13. Nov 19, 20214 OWNERSHIP DOCUMENT EDGAR
  14. Nov 19, 20214 OWNERSHIP DOCUMENT EDGAR
  15. Nov 19, 20214 OWNERSHIP DOCUMENT EDGAR
  16. Nov 19, 20214 OWNERSHIP DOCUMENT EDGAR
  17. Nov 19, 20214 OWNERSHIP DOCUMENT EDGAR
  18. Nov 19, 2021SC 13D/A GROWTH EQUITY OPPORTUNITIES FUND V, LLC - TRILLIUM THERAPEUTICS -- SCHEDULE 13D/ EDGAR
  19. Nov 17, 2021S-8 POS EDGAR
  20. Nov 17, 2021S-8 POS EDGAR

The 35 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Trillium Therapeutics Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARTrillium Therapeutics Inc.1
  • CIK0001616212
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inBritish Columbia, Canada1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address2488 Dunwin Drive, Mississauga, A6 L5L 1J91
  • Phone(416) 595-06271
  • Shares outstanding104,995,125 as of Nov 10, 202130
  • Public float$684.0M as of Jun 30, 20203
  • On EDGAR sinceAug 12, 20141
  • Filings358 in all: 6-K (148), 4 (36), SC 13G/A (27), SC 13G (21), 3 (16), 8-K (16), CORRESP (9), DEFA14A (7)1
    All 43 form types

    EFFECT (7), SUPPL (7), UPLOAD (7), SC 13D/A (5), 40-F (4), 424B5 (4), 10-Q (3), F-10/A (3), F-X (3), 20-F (2), 20FR12B/A (2), 40-F/A (2), F-1/A (2), F-10 (2), F-3 (2), POS AM (2), S-8 (2), S-8 POS (2), 10-K (1), 15-12B (1), 20FR12B (1), 25-NSE (1), 424B1 (1), CERTNAS (1), CT ORDER (1), D (1), DEF 14A (1), DEFM14A (1), F-1 (1), F-3/A (1), FWP (1), POSASR (1), PREM14A (1), S-3ASR (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Mar 18, 2021
    Quarterly report (10-Q) Nov 12, 2021
    Proxy statement (DEF 14A) Apr 30, 2021
    Latest 8-K (8-K) Nov 17, 2021

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
    SEC EDGAROther events
  23. 23
    SEC EDGAROther events
  24. 24
  25. 25
    SEC EDGAROther events
  26. 26
    SEC EDGAROther events
  27. 27
    SEC EDGAROther events
  28. 28
  29. 29
  30. 30